Thyroid dysfunction in a UK hepatitis C population treated with interferon- and ribavirin combination therapy

Clinical Endocrinology

Volumn 73, Issue 2, 2010, Pages 249-256

  Costelloe, Seán J ^a   Wassef, Nancy ^a   Schulz, Josephine ^a   Vaghijiani, Tina ^a   Morris, Catherine ^a   Whiting, Stephen ^a   Thomas, Michael ^a   Dusheiko, Geoffrey ^a   Jacobs, Michael ^a   Vanderpump, Mark P J ^a  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; LEVOTHYROXINE; PEGINTERFERON ALPHA2A; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; THYROID PEROXIDASE; THYROID PEROXIDASE ANTIBODY; THYROTROPIN;

ADULT; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; FEMALE; FREE THYROXINE INDEX; GRAVES DISEASE; HEPATITIS C; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; THYROID DISEASE; THYROID FUNCTION; THYROID SCINTISCANNING; THYROIDITIS; THYROTROPIN BLOOD LEVEL; UNITED KINGDOM;

ADULT; AGE OF ONSET; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GREAT BRITAIN; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; THYROID DISEASES;

EID: 77954883185     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2010.03785.x     Document Type: Article

References (28)

1. WHO 2002) Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. Journal of viral hepatitis, 6, 35 47.
2. Antonelli, A., Ferri, C., Pampana, A. et al. (2004) Thyroid disorders in chronic hepatitis C. The American journal of medicine, 117, 10 13.
3. Antonelli, A., Ferri, C., Ferrari, S.M. et al. (2009) Endocrine manifestations of hepatitis C virus infection. Nature Clinical Practice Endocrinology & Metabolism, 5, 26 34.
4. Sievert, W. (2001) An overview of antiviral therapy for chronic hepatitis C infection. In:N. Crofts, G. Dore, S. Locarnini eds. Hepatitis C: an Australian perspectiv. IP Communications
5. Prummel, M.F. Laurberg, P. (2003) Interferon- and Autoimmune Thyroid Disease. Thyroid, 13, 547 551.
6. Tran, H.A., Attia, J.R., Jones, T.L. et al. (2007) Pegylated interferon-alpha2beta in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-alpha2beta in a hepatitis C population: meta-analysis. Journal of gastroenterology and hepatology, 22, 472 476.
7. Paraná, R., Cruz, M., Santos-Jesus, R. et al. (2000) Thyroid disease in HCV carriers undergoing antiviral therapy with interferon plus ribavirin. The Brazilian journal of infectious diseases, 4, 284 290.
8. Kryczka, W., Brojer, E., Kowalska, A. et al. (2001) Thyroid gland dysfunctions during antiviral therapy of chronic hepatitis C. Medical science monitor, 7 Suppl 1:221 225.
9. Carella, C., Mazziotti, G., Morisco, F. et al. (2002) The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism. European journal of endocrinology, 146, 743 749.
10. Bini, E.J. Mehandru, S. (2004) Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study. Archives of internal medicine, 164, 2371 2376.
11. Tran, H., Jones, T. Batey, R. (2005) The spectrum of thyroid dysfunction in an Australian hepatitis C population treated with combination Interferon-alpha2beta and Ribavirin. BMC Endocrine Disorders, 5, 8.
12. Wirth, S., Pieper-Boustani, H., Lang, T. et al. (2005) Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology, 41, 1013 1018.
13. Kee, K.M., Lee, C.M., Wang, J.H. et al. (2006) Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis. Journal of gastroenterology and hepatology, 21, 319 326.
14. Huang, J.F., Chuang, W.L., Dai, C.Y. et al. (2006) The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy. Journal of viral hepatitis, 13, 396 401.
15. Gehring, S., Kullmer, U., Koeppelmann, S. et al. (2006) Prevalence of autoantibodies and the risk of autoimmune thyroid disease in children with chronic hepatitis C virus infection treated with interferon-alpha. World journal of gastroenterology, 12, 5787 5792.
16. Kowala-Piaskowska, A., Mozer-Lisewska, I., Figlerowicz, M. et al. (2007) Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C. Pharmacoepidemiology and drug safety, 16, 1095 1103. (Pubitemid 350020062)
17. Plöckinger, U., Kruger, D., Bergk, A. et al. (2007) Hepatitis-C patients have reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-alpha. The American journal of gastroenterology, 102, 2724 2731.
18. Masood, N., Ghori, R., Memon, A. et al. (2008) Frequency of thyroid disorders during interferon and ribavirin therapy in chronic hepatitis C infection. Journal of the College of Physicians and Surgeons-Pakistan, 18, 347 351.
19. Tran, H.A., Reeves, G.E. Jones, T.L. (2009) The natural history of interferon-alpha2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection. QJM:monthly journal of the Association of Physicians, 102, 117 122.
20. Tarantino, G., Gagliardi, G. Conca, P. (2009) Do thyroid abnormalities detected in patients treated for HCV-related chronic hepatitis persist? International journal of immunopathology and pharmacology, 21, 467 469.
21. Friedrich-Rust, M., Theobald, J., Zeuzem, S. et al. (2009) Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C. Journal of viral hepatitis, 16, 168 177.
22. Vezali, E., Elefsiniotis, I., Mihas, C. et al. (2009) Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related? Journal of gastroenterology and hepatology, 24, 1024 1029.
23. Nadeem, A., Aslam, M., Khan, D.A. et al. (2009) Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C. Journal of the College of Physicians and Surgeons-Pakistan, 19, 86 89.
24. Jamil, K.M., Khaleel, M., Leedman, P.J. et al. (2009) Interferon-induced thyroid dysfunction in chronic hepatitis C. Journal of Gastroenterology and Hepatology 24, 1017 1023.
25. Gelu-Simeon, M., Burlaud, A., Young, J. et al. (2008) Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. World journal of gastroenterology, 15, 328 333.
26. Biondi, B. Cooper, D.S. (2008) The clinical significance of subclinical thyroid dysfunction. Endocrine Reviews, 29, 76 131.
27. Vanderpump, M.P., Tunbridge, W.M., French, J.M. et al. (1995) The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clinical Endocrinology, 43, 55 68.
28. Geul, K.W., van Sluisveld, I.L., Grobbee, D.E. et al. (1993) The importance of thyroid microsomal antibodies in the development of elevated serum TSH in middle-aged women: associations with serum lipids. Clinical Endocrinology, 39, 275 280.